Ireland What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere) is one factor, but it doesn’t end there. Talent: “The first factor is the excellence of the workforce, which is…
Contract Manufacturing It is widely acknowledged that pharmaceutical manufacturing operations have entered into a period of significant cost reduction. Service providers like Dalkia—a French energy services company that has built its Irish business upon serving the pharmaceutical sector—have had to help clients cope. Dalkia Ireland’s managing director Pat Gilroy remembers his years…
Clinical trials The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative molecule PI-88. He also offers his perspective on the increasing synergies between Taiwan and China in the biotech sector. During our…
Generics Fergal Murphy, Chairman of the Association of Pharmaceutical Manufacturers in Ireland, discusses with pharamaboardroom.com the difficulties in such a small market and how the industry is adapting to the needs of Ireland by working closely with the government to find the right price point for products and increasing awareness of…
Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…
Generics Eric Ng received his degree at National University of Singapore. In his career he has worked for such companies as AstraZeneca before moving to Sanofi-Aventis China until his rise in rank to President Director of Sanofi in Indonesia. Today he talks about the stiff competition in Indonesia in the generics…
Mexico In the late 1990s, Rodrigo Herrera Aspra wanted to commercialize a new anti-acne formulation, and was advised by a friend who was involved in the pharmaceutical industry to hire a group of medical reps. “After thinking on this issue, I concluded there was something wrong with a business model in…
maintenance Mr. O’Neill, you have been managing director of this company for 17 years. How have you evolved the business over that period? ESS was founded in 1991, and I joined the business in 1996. The company’s initial vision was to provide flexibility to the maintenance market in Ireland and its…
Genzyme - Ireland Mr. Martin, you were appointed as Genzyme’s GM for UK and Ireland last month after having spent a decade at the organization. Robin Kenselaar, Head of Genzyme EMEA, noted that your appointment came at a “key time for the business.” What is your understanding of where this company is going…
ThromboGenics Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud of? At the moment, ThromboGenics basically has one key product, Ocriplasmin, which has recently completed phase-III clinical studies. Initially, this…
Cegedim Belgium October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career at Therabel and B Braun – both pharmaceutical and medical devices companies, apply to Cegedim? What were some of main…
See our Cookie Privacy Policy Here
